You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.
A new sequencing-based method developed by Duke University's Kate Meyer is one of several that can detect RNA methylation without the use of antibodies.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The San Francisco-based startup, which closed a $5 million Series A round in 2017, aims to develop nutritionally enhanced food and feed crops.
Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.